Objective: Many side effects including elevation of intraocular pressure (IOP) due to long-term use of intranasal steroids were reported, especially with the first generation intranasal steroids, yet the second generation intranasal steroids were believed only having a minimal impact on IOP because of low bioavailability. The object of this study was to assess the value of IOP for assessing the ocular safety of two intranasal steroids (the first generation and the second generation) for treatment of 12-week period. Methods: Fifty two allergic rhinitis patients were divided randomly into two groups using either the first or second generation intranasal steroids for 12 weeks, respectively. IOPs were measured before treatment and after the 3rd, 6th, 9th, and 12th weeks of treatment. The IOPs of the two groups were compared. Results: The IOP of the first-generation intranasal steroids at 3, 6 and 9 weeks after treatment were not statistically different from those before treatment, while the IOP at 12 weeks after treatment were statistically different from those before treatment. Meanwhile, there were no statistically significant differences between the IOP at various stages of treatment and that before treatment with the use of second generation intranasal steroids. Conclusions: For patient with long standing use of nasal steroids, IOP could be considered as an important index for assessing the ocular safety.